Rana Saad1, Sami Saad2, Oscar Haigh3, Domitille Molinari4, Marc Labetoulle1,3, Antoine Rousseau5,6. 1. Service d'Ophtalmologie, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Université Paris-Saclay, Centre de Référence Maladies Rares en Ophtalmologie (OPHTARA), 78, rue du Général Leclerc, 94275, Le Kremlin Bicêtre, France. 2. Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts, Paris, France. 3. CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT), Fontenay-aux-Roses, Le Kremlin-Bicêtre, France. 4. Unité de Recherche Clinique Paris-Sud, Hôpital Bicêtre, Le Kremlin Bicêtre, France. 5. Service d'Ophtalmologie, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Université Paris-Saclay, Centre de Référence Maladies Rares en Ophtalmologie (OPHTARA), 78, rue du Général Leclerc, 94275, Le Kremlin Bicêtre, France. antoine.rousseau@aphp.fr. 6. CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT), Fontenay-aux-Roses, Le Kremlin-Bicêtre, France. antoine.rousseau@aphp.fr.
Abstract
BACKGROUND: Thygeson's superficial punctate keratitis (TSPK) is a rare and still poorly understood disease of the ocular surface, responsible for recurrent episodes of photophobia and eye pain. While TSPK is considered as a benign condition, a subset of patients has frequent recurrences or even chronic disease, two situations in which there are currently no therapeutic guidelines. We used a preexisting Facebook TSPK patient support group to assess the clinical journey and the burden of disease of TSPK. RESULTS: An online survey was sent to the patient support group. The first part of the questionnaire gathered information on demographics and the patient's clinical journey [diagnostic modalities, symptoms, duration and frequency of recurrent episodes (RE), efficacy and tolerance to treatments]. The second part focused on quality of life (QoL) using the Ocular Surface Disease-QoL (OSD-QoL) questionnaire. Seventy-two patients out of 595 members of the support group completed the questionnaire during the 3-months study period. Eighty percent of patients developed symptoms before 30 years old, and 47% reported a delay in the diagnosis above 1 year. Sixty percent of patients reported over 5 RE yearly, and 18% of RE lasted more than 3 months. Forty percent of all patients used cyclosporine eyedrops (50% of those with > 5 episodes/year) and it was perceived as effective by 72% of these patients. The impact on daily life activities was judged as severe by 22% of patients, while 38% reported reduced professional activity and 80% were deeply saddened by their eye condition. CONCLUSION: TSPK patients may present with frequent recurrences and/or chronic disease, that result in a severe impact on QoL, and an off-label use of topical immunomodulatory eye drops, suggesting the urgent need for controlled studies. The utility of using social networks for rare ophthalmic disease research includes, faster data collection, data from patients across the globe, and also raises relevant questions about their real needs.
BACKGROUND: Thygeson's superficial punctate keratitis (TSPK) is a rare and still poorly understood disease of the ocular surface, responsible for recurrent episodes of photophobia and eye pain. While TSPK is considered as a benign condition, a subset of patients has frequent recurrences or even chronic disease, two situations in which there are currently no therapeutic guidelines. We used a preexisting Facebook TSPK patient support group to assess the clinical journey and the burden of disease of TSPK. RESULTS: An online survey was sent to the patient support group. The first part of the questionnaire gathered information on demographics and the patient's clinical journey [diagnostic modalities, symptoms, duration and frequency of recurrent episodes (RE), efficacy and tolerance to treatments]. The second part focused on quality of life (QoL) using the Ocular Surface Disease-QoL (OSD-QoL) questionnaire. Seventy-two patients out of 595 members of the support group completed the questionnaire during the 3-months study period. Eighty percent of patients developed symptoms before 30 years old, and 47% reported a delay in the diagnosis above 1 year. Sixty percent of patients reported over 5 RE yearly, and 18% of RE lasted more than 3 months. Forty percent of all patients used cyclosporine eyedrops (50% of those with > 5 episodes/year) and it was perceived as effective by 72% of these patients. The impact on daily life activities was judged as severe by 22% of patients, while 38% reported reduced professional activity and 80% were deeply saddened by their eye condition. CONCLUSION: TSPK patients may present with frequent recurrences and/or chronic disease, that result in a severe impact on QoL, and an off-label use of topical immunomodulatory eye drops, suggesting the urgent need for controlled studies. The utility of using social networks for rare ophthalmic disease research includes, faster data collection, data from patients across the globe, and also raises relevant questions about their real needs.
Entities:
Keywords:
Burden of disease; Clinical journey; Quality of life; Social network; Thygeson’s superficial punctate keratitis
Authors: C Baudouin; C Creuzot-Garcher; T Hoang-Xuan; M-C Rigeade; Y Brouquet; A Bassols; K Benmedjahed; B Arnould Journal: J Fr Ophtalmol Date: 2003-02 Impact factor: 0.818
Authors: C Baudouin; C Creuzot-Garcher; T Hoang-Xuan; M-C Rigeade; Y Brouquet; A Bassols; I Guillemin; K Benmedjahed; B Arnould Journal: J Fr Ophtalmol Date: 2008-04 Impact factor: 0.818
Authors: Kei Long Cheung; Peter M Ten Klooster; Cees Smit; Hein de Vries; Marcel E Pieterse Journal: BMC Public Health Date: 2017-03-23 Impact factor: 3.295